All News
EULAR 2026: Industry Press Releases
Pharmaceutical companies are presenting pivotal clinical trial results and key data analyses at the EULAR 2026 Congress (June 3–6, London). Below is a summary of their most important studies — many of which are registration-enabling or will directly shape treatment decisions in rheumatic diseases.
Read Article
Quiz Talk (5.22.2026)
Dr. Jack Cush talks of birthdays, Quizzes and journal articles this week on the podcast.
Read Article
BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA
UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6.
Read Article
Immune-Mediated Inflammatory Diseases Following Uveitis
A Korean insurance claims data study showed children and adolescents diagnosed with uveitis have a 7-fold increased risk of developing an immune-mediated inflammatory disorder (IMID).
Read Article
At Week 52 with izokibep in #PsA PASI90: 63–69%; PASI100: 55–64%; MDA: 47–52%. The small-molecule format may enable deeper tissue penetration. Novel anti-IL-17 approach. Abstr#073 @RheumNow #EULAR2026 #Biologics https://t.co/IaJ1gyECZu
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Izokibep (novel small IL-17A inhibitor, 18.6 kDa) maintained efficacy to Week 52 in active #PsA with ~50% of patients achieving ACR50 and nearly half reaching MDA. Sustained durable response with no new safety signals Abstr#OP073 @RheumNow #EULAR2026 https://t.co/Y6fTirE886
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
In a 17-year real-world psoriasis cohort, patients on IL-17i had 75% lower odds and IL-23i patients had 84% lower odds of developing #PsA vs TNF inhibitors. Is biologic class selection a PsA interception strategy? Prospective controlled trials are needed Abstr#072 @RheumNow https://t.co/jpdZjGK7VV
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
TOGETHER PsA trial
IXE+TIRZEPATIDE TZP vs. IXE alone RCT
Obese or Overweight PsA IR to <3 bioDMARDs
Primary endpoint ≥10% weight & ACR50 wk 36
31.7% IXE+TZP vs. 0.8% for IXE alone
ACR50 IXE+TZP 33.5% & IXE 20.4%, p=0.02)
No clear difference by gender/age/BMI/previous DMARDs https://t.co/zBcfpj2MF6
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
Treating inflammation and obesity in PsA with IXEKIZUMAB AND CONCOMITANT TIRZEPATIDE effective with no new safety signals
OP069 @RheumNow #EULAR2026 https://t.co/rkhYvZWpHn
Jiha Lee JihaRheum ( View Tweet)
Small interventional synovial biopsy precision medicine study
CD117 high pts n=15 = better response to IL17i or IL23i inhibition vs. TNFi w/
-DAPSA -13.5, -12.8 vs. -7.5 respectively
Higher BL levels of tissue inflammation in Responders vs. NR
More robust study design needed https://t.co/7jNff6lUJ6
Aurelie Najm AurelieRheumo ( View Tweet)
💊 Oral IL-23Ri for #PsA #PsO?
ICONIC RCT (n=216):
Yes! Icotrokinra improves pain & disease activity at week 16
#POS0052 #EULAR2026 @RheumNow https://t.co/PA4O36h02Y
Nelly ZIADE 🍀 Nellziade ( View Tweet)
🛡️ Can secukinumab prevent #PsA?
SERENA real-world study (n=1,334):
Yes!
97% PsA-free at 5yrs
#POS0051 #EULAR2026 @rheumnow
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Nail #PsA, hard to treat and often overlooked. APEX trial: guselkumab achieved 43% ↓ in nail severity score (mNAPSI) vs 16% worsening on placebo at wk 24, plus PASI 100 in ~39% vs 11%. IL-23 inhibition delivering where pts often struggle most. @RheumNow #EULAR2026 POS0471
Jiha Lee JihaRheum ( View Tweet)
🤔 GUS or IL-17i for #PsA?
#POS0045: RW study:
Both! ~76% persistence & similar effectiveness
1141 pts @12mo #PsABIOnd 🌍
#EULAR2026 @RheumNow https://t.co/PyuaH5B5V1
Nelly ZIADE 🍀 Nellziade ( View Tweet)
IL-23i vs IL-17i in PsABIOnd (n=1,141): 12mo persistence (~77%), joint/skin response, MDA, and PROs similar across both. GUS matched IL-17i despite treating more biologic-experienced pts (15% vs 8% on 4th-line). GI AEs higher with IL-17i (11% vs 7%). @RheumNow #EULAR2026 POS0045
Jiha Lee JihaRheum ( View Tweet)
What’s new in (WIN) PsA session. A preview of the BE BOLD study: Bimekizumab vs risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.008). The first head-to-head biologic trial to show joint superiority in PsA. Dual IL-17A/F blockade important. Abstr #LB0001 @RheumNow
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA
UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6. This head-to-head trial demonstrates that at week 16, bimekizumab (BKZ) yielded superior ACR50 https://t.co/VVBaNdWIuQ
Dr. John Cush RheumNow ( View Tweet)
Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis
Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and tolerable. https://t.co/4WMLbcPLOs
Dr. John Cush RheumNow ( View Tweet)
Prospective study of 40 newly Dx, Tx-naïve RA pts starting MTX; Of serum cytokines tested, high baseline IL-6 & IL-17 was assoc w/ nonresponse to MTX. Yet, still not good response biomarkers. TNF-α & GM-CSF did not assoc w/ MTX outcomes https://t.co/YIQKop9LMH https://t.co/XxwcRsKwoM
Dr. John Cush RheumNow ( View Tweet)
Another IL-17A inhibitor (Vunakizumab) for active Ankylosing Spondylitis
Vunakizumab, a novel anti–interleukin (IL) 17A monoclonal antibody, was studied in patients with active radiographic axial spondyloarthritis [r-axSpA] and found to be effective and tolerable. https://t.co/y0mw7tRWbs
Dr. John Cush RheumNow ( View Tweet)
